Objective. Hypothyroid patients are treated by sodium levothyroxine (LT4). Tablet is the mostly used LT4 formulation, and the\nfasting regimen is required for the absorption of active principle. Also, gastrointestinal diseases and drugs may impair the LT4\nbioavailability when tablet is used. Nonsolid LT4 formulations (i.e., liquid solution (LS) and soft gel (SG) capsule) were\nmanufactured to overcome the limitations of LT4 tablet. This study was conceived to evaluate the performance of nonsolid LT4\nformulations in a real-life scenario. Methods. Two institutions participated in the study that was conducted in two phases (i.e.,\nenrollment and re-evaluation). Adults with autoimmune or postsurgical hypothyroidism and on LT4 from a few months were\nselected. A nonparametric statistical analysis for paired or unpaired data was performed. Results. 121 consecutive cases were\nincluded. At the enrollment phase, a 52% of patients took the therapy at least 30 min before breakfast with no difference between\ntablet and SG/LS users..............................
Loading....